《医疗器械临床试验质量管理规范》英文版_第1页
《医疗器械临床试验质量管理规范》英文版_第2页
《医疗器械临床试验质量管理规范》英文版_第3页
《医疗器械临床试验质量管理规范》英文版_第4页
《医疗器械临床试验质量管理规范》英文版_第5页
已阅读5页,还剩27页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

《医疗器械临床试验质量管理规范》英文版StateFoodandDrugAdministration

NationalHealthandFamilyPlanningCommission

Numbertwenty-fifth

<medicalequipmentspecificationforthequalitycontrolofclinicaltrialof>hasbeenstatefoodandDrugAdministrationintheexecutivemeetingofthe,nationalhealthandFamilyPlanningCommission,directorofthecommitteemeetingexaminedandadopted,isherebypromulgated,sinceJune1,2016implementation.

DirectorBiJingquan

DirectorLiBin

March1,2016

Standardforqualitymanagementofmedicaldeviceclinicaltrials

Chapteroneisthefirstchapter

Thefirstistostrengthenthemanagementofmedicaldeviceclinicaltrials,themaintenanceprocessforclinicaltrialsofmedicaldevicesinrightsandinterests,andtoguaranteethemedicaldeviceclinicaltrialsprocessspecification,realresults,science,reliableandtraceable,accordingto<thesupervisionandadministrationofMedicalDevicesRegulations>formulatedthisspecification.

Article2withintheterritoryofthepeople'sRepublicofChinatocarryouttheclinicaltrialofmedicalapparatusandinstruments,shallcomplywiththespecification.Thisspecificationcoversthewholeprocessofmedicaldeviceclinicaltrials,includingdesignofclinicaltrials,theimplementationof,monitoring,verification,inspection,anddataacquisition,record,andanalyzethesummarizingandreporting.

Thethirdsectionofthisspecificationreferredtointheclinicaltrialofmedicalapparatusandinstruments,referstointheaccreditationofmedicalinstrumentclinicaltrialinstitution,intendstoapplyfortheregistrationofmedicaldeviceinthenormalconditionsofuseissafeandeffectiveforconfirmationorverificationprocess.

Fourthclinicaltrialsofmedicaldevicesshallcomplywiththeprinciplesoflaw,ethicalprinciplesandscientificprinciples.

Article5atorabovetheprovinciallevelfoodanddrugsupervisionandmanagementdepartmentsresponsibleforthesupervisionandmanagementofmedicaldeviceclinicaltrials.Healthandfamilyhealthdepartmentincharge,withinitsscopeoffunctionsandduties,strengthentheclinicaltrialofmedicalapparatusandinstrumentsmanagement.Foodanddrugsupervisionandmanagementdepartments,healthandfamilyhealthdepartmentsshouldestablishthemedicalqualityofclinicaltrialmanagementinformationreportingmechanism,strengthentheclassIIImedicaldevices,includedinthenationalconfigurationoflargemedicalequipmentqualitymanagementobjectiveofmedicalapparatusandinstrumentstocarryoutexaminationandapprovalofclinicaltrialsandthecorrespondingclinicaltrialsupervisionandmanagementofdatacommunications.

Thesecondchapteristhepreparationbeforeclinicaltrial

Article6theclinicaltrialofmedicalapparatusandinstrumentsshallhavesufficientscientificbasisandtheclearpurposeofthetest,andweighonexpectedandthepublichealthbenefitandrisk,expectedbenefitshouldexceedthepossibledamage.

Article7beforeclinicaltrials,thesponsorshalltestdoneinpreclinicalstudiesofmedicalapparatusandinstruments,includingproductdesign(structure,workingprincipleandmechanismofaction,isexpectedtouseandscopeofapplication,theapplicabletechnicalrequirementsandqualityinspection,animaltestingandriskanalysisandresultsshouldbeabletosupporttheclinicaltrial.Qualityinspectionresultsincludingselfinspectionreportandaqualifiedinspectionagencyissuedayearwithintheproductregistrationinspectionreport.

Priortotheeighthclinicaltrials,theapplicantshouldprepareadequatetestingofmedicalequipment.Thedevelopmentofthetestwithmedicalequipmentshallmeettheapplicablerequirementsofthemedicaldevicequalitymanagementsystem.

Thenineclinicaltrialsofmedicaldevicesshallbeintwoormorethantwomedicaldeviceclinicaltrialinstitution.Selectedtestinginstitutionsshallbewithoutqualificationaccreditationofmedicalinstrumentclinicaltrialinstitution,andfacilitiesandconditionsshallmeetthesafetyeffectivelyclinicaltrialexperience.Researchersshouldbeabletobeartheclinicaltrialsofspecialty,qualificationandabilityandtrained.QualificationofmedicalinstrumentclinicaltrialinstitutionidentifiedmanagementmeasuresshallbeformulatedseparatelybytheStateFoodanddrugadministrationshall,jointlywiththeMinistryofhealthandFamilyPlanningCommission.

Article10beforeclinicaltrials,thesponsorandclinicaltrialinstitutionsandresearchersshouldtestdesign,testqualitycontrol,testthedivisionofresponsibilities,sponsortobearthecostsassociatedwiththeclinicaltrialandtestinmayoccurdamagedealingwithprinciplestoreachawrittenagreement.Article11clinicaltrialsshouldobtainconsentoftheclinicaltrialofmedicalapparatusandinstrumentsinstitutionalethicscommittee.IncludedintheneedforclinicaltrialsandapprovalofclassIIImedicaldevicesdirectory,shouldalsobeapprovedbytheStateFoodanddrugadministration.

Article12priortoclinicaltrials,thesponsorshallbetothelocationofprovinces,autonomousregions,municipalfoodanddrugsupervisionandmanagementdepartmentsfortherecord.Acceptfilingoffoodanddrugsupervisionandadministrationdepartmentshallrecordthesituationinformedclinicaltrialinstitutionislocatedatthesameleveloffoodanddrugsupervisionandmanagementdepartments,aswellashealthandfamilyhealthdepartments.

Thethirdchapteristheprotectionoftherightsandinterestsofthesubjects

ThirteenthclinicaltrialsofmedicaldevicesshallcomplywiththeethicalstandardssetbytheHelsinkideclarationoftheworldmedicalassembly.

Thefourteenthethicalreviewandinformedconsentarethemainmeasurestoprotecttherightsandinterestsofthesubjects.Thepartiesinvolvedinclinicaltrialsshouldassumethecorrespondingethicalresponsibilitiesaccordingtotheirrespectiveresponsibilities.

Article15thesponsorshouldavoidundueinfluenceormisleadingtosubjects,clinicaltrialsandresearchandclinicaltrialparticipantsorrelatedparty.Clinicaltrialinstitutionsandresearchersshouldavoidundueinfluenceormisleadingtosubjects,thesponsorandotherparticipantsinclinicaltrialsorinterestedparties.

Sixteenthapplicants,clinicaltrialsandresearchersshouldnotexaggeratethecompensationmeasuresinvolvedinclinicaltrials,tomisleadtheparticipantstoparticipateinclinicaltrials.

Seventeenthpreclinicaltrials,theapplicantshallsubmitthefollowingdocumentstotheethicscommitteebyresearchersandclinicaltrialinstitutionofmedicalinstrumentclinicaltrialmanagement:(a)clinicaltrialprogram;(two)researchersmanual;(three)writteninformedconsentdocumentandanyotheravailabletoparticipants(;four)recruitingsubjectsandproceduraldocumentstoitspropaganda;(five)thecasereportformtext;(six)selfinspectionreportandproductregistrationinspectionreport;(seven)researchersresume,professionalexpertise,skills,trainingandotherdocumentstoprovetheirqualifications;(eight)clinicaltrialinstitutionthefacilitiesandconditionstomeetthetestreview;(nine)withthedevelopmentofmedicaldevicesinaccordancewiththerelevantrequirementsofmedicalqualitymanagementsystemfortheteststatement;(ten)otherdocumentsrelatedtoethicalreview.Ethicscommitteeshallupholdtheprinciplesofethicsandscience,reviewandsupervisetheimplementationofclinicaltrials.

Eighteenthoneofthefollowingcircumstancesoccurinthecourseofclinicaltrials,researchersshouldreporttotheclinicaltrialinstitutionofmedicalinstrumentclinicaltrialmanagementdepartment,andthetimelynotificationoftheapplicant,theethicscommitteereport:(a)seriousadverseevents;(two)progressreport,includingasummaryofsafetyanddeviationreports;(three)foranyamendmenthasbeenapprovedbytheethicscommitteeofthefile,doesnotaffecttherightsandinterestsofthesubjects,safetyandhealth,nonsubstantivechangeswithoutpriorreportsorclinicaltrialswiththepurposeorendnotrelated,butafterwardsshallnotifyinwriting;(four)tosuspend,terminateorsuspendtherequestaftertherecoveryofclinicaltrials(five;)affecttherightsandinterestsofthesubjects,fromclinicaltrialsorclinicaltrialsafetyandhealthscience,includingthedeviationofrequestandreportthedeviation.FortheprotectionofsubjectsWhereaperson'srights,securityandhealtharenotimmediatelyreportedinanemergency,itshallbereportedinwrittenformassoonaspossibleinaccordancewiththerelevantprovisions.

Article19intheprocessofclinicaltrials,asamendedclinicaltrialprotocolsandinformedconsentdocuments,requestdeviation,resumeapausedclinicaltrialsshouldbecancontinuetoimplementuntilitobtainthewrittenapprovaloftheethicscommittee.

Itisgoodtothehealtharticle20shouldbeavoidedasfaraspossibleselectionofminors,pregnantwomen,elderly,personswithmentalobstacleinlifecriticalpatientsassubjects,thatreallyneedtobeselected,itshallabidebytheethicscommitteeoftheadditionalrequirement.Inclinicaltrialsfortheirhealthisspeciallydesigned,andshouldbe.article20shouldbeavoidedasfaraspossibleselectionofminors,pregnantwomen,elderly,personswithmentalobstacleinlifecriticalpatientsassubjects,thatreallyneedtobeselected,itshallabidebytheethicscommitteeoftheadditionalrequirement.Inclinicaltrialsfortheirhealthisspeciallydesigned,andshouldbe.

Article21insubjectsinclinicaltrials,researchersshouldfullytosubjectsornocapacityforcivilconduct,theguardianofthepersonofcivilactioncompetencelimitthatthedetailsoftheclinicaltrials,includingtheknown,itcanbepredictedtheriskandpossibleadverseevents.AfterfullanddetailedexplanationbythesubjectsortheirguardiansininformedconsentBooksignyournameanddate,researchersalsoneedtoininformedconsentBooksignyournameanddate.

Twenty-secondgeneralconsentshallincludethefollowingcontentsanddescriptionofmatters:(a)theresearchersnameandrelevantinformation;(two)thenameofclinicaltrialinstitution;(three)thenameofthetrial,purpose,method,content;(four)testprocess,testperiod;(five)thesourcesoffundsandthepossibleconflictsofinterest;(six)theexpectedparticipantsmaybenefitandknown,riskcanbeforeseenandadverseeventsmayoccur;(seven)alternativetreatmentsubjectscanobtaintheinformationanditspotentialbenefitsandrisks;(eight)whenneeded,thatsubjectsmaybeassignedtodifferentgroupsofexperiments;(nine)subjectsparticipatedintheexperimentshouldbevoluntary,andatanystageofthetesthastherighttowithdrawwithoutdiscriminationorrevenge,themedicaltreatmentandTherightsandinterestsarenotaffected;(ten)toldthesubjectsinthestudyofpersonaldataisconfidential,buttheethicscommittee,foodanddrugsupervisionandmanagementdepartments,healthdepartmentsorsponsoratworkwhennecessaryinaccordancewiththeprescribedprocedures,canrefertothesubjectsinthestudyofpersonaldata;(eleven)ashappenedwiththerelatedtestthehurt,thesubjectscouldgettreatmentandeconomiccompensation;(twelve)thesubjectscanunderstandtherelatedinformationduringthetest;(thirteen)freeclinicprojectparticipantsmaybeobtainedduringthetestandotherrelatedsubsidies.Informedconsentshallbeadoptedbythesubjectsorguardianscanunderstandthelanguageandtext.Informedconsentshallnotcontainanycausesubjectstogiveupthelegitimaterightsandinterestsandexemptionfromclinicaltrialinstitutionsandresearchers,thesponsororTheagentshallberesponsibleforthecontent.

Twenty-thirdobtaininformedconsentshallalsomeetthefollowingrequirements:(a)thesubjectsincapacitated,iftheethicscommitteeagreedinprinciple,researchersbelievethatthesubjectsparticipatinginaclinicaltrialwithitsowninterests,canalsoenterclinicaltrials,butshouldtryandmarkedbytheGuardianSignatureDateprior.;(two)thesubjectsortheirguardianswithoutreadingability,intheprocessofknowledgeshouldhaveawitnesspresent,afteradetailedexplanationoftheinformedconsent,witnessesreadtheinformedconsentandoralinformedcontent,agreedtobythesubjectsortheircarepopulationhead,witnessesininformedconsentthebookofsignatureanddate,signatureofwitnessandtheresearcher'ssignatureshouldbeonthesameday.;(three)minorsassubjects,shouldobtaintheconsentoftheguardianandsignedinformedconsentDepartmentinformedconsent,minorsonwhethertoparticipateintestinganintention,shouldalsobetheirconsent.;(IV)foundrelatestomedicalapparatusandinstrumentsofimportantinformationorareexpectedtotesttheclinicalimpactofshallbeofinformedconsentbookcontentismodified,themodifiedinformedconsentbytheethicscommitteeapprovalshallbebythetestoritsguardianresignatureconfirmation.

Article24informedconsentbookshallbeindicatedintheformulationofdateorrevisedversionsofdate.Suchasinformedconsentinthetestintheprocessofrevision,revisedversionoftheinformedconsentimplementthebookbeforeagainbytheethicscommitteeagreedto.Revisededitionofinformedconsentbooksclinicaltrialmechanismafter,allbeforetheendofthetestprocessofthesubjectswereasaffectedbytheshallsignedtheinformedconsentforthenewlyrevised.

Twenty-fifthsubjectshavetherighttowithdrawfromanystageofclinicaltrialsandarenotsubjecttoanyfinancialresponsibility.Thefourthchapterclinicaltrialprogram

Twenty-sixthtocarryoutclinicaltrialsofmedicaldevices,theapplicantshouldbeinaccordancewiththecategoriesofmedicalequipmenttesting,risk,intendeduse,andotherorganizationstodevelopscientificandrationalclinicaltrialsprogram.

Article27notinsideandoutsidetheapprovedthelistingofnewproducts,safetyandperformancehasnotbeenconfirmedbymedical,clinicaltrialdesignshouldfirstconductafeasibilitytestforsmallsamples,tobeinitiallyrecognizedfortheirsafety,accordingtothestatisticalrequirementstodeterminethesamplesizetocarryoutthefollowingclinicaltrial.

Twenty-eighthclinicaltrialsprotocolshouldincludethefollowing:(a)generalinformation;(two)thebackgrounddatainclinicaltrials;(three)thepurposeoftheexperiment;(four)experimentaldesign;(five)safetyevaluationmethod;(six)effectivenessevaluationmethod;(seven)statisticalconsiderations;(eight)theprovisionsforclinicaltrialsprogram;(nine)theprovisionsofadverseeventsandequipmentdefectreport;(ten)directaccesstothesourcedatafile;(eleven)clinicaltrialsinvolvingethicalissuesandinstructionsandinformedconsentdocument;(twelve)dataprocessingandrecordkeeping;(thirteen)financialandinsurance;(fourteen)agreement.Thetestresultswerepublishedpartofthecontentscanbeincludedinotherrelateddocumentssuchasprojectresearchers.HandbookofclinicaltrialsSpecificinformationabouttheorganization,theresultsofthetrialpublishedagreement,financeandinsurancecanbeexpressedinthetestplan,youcanalsomakeaseparateagreementtobespecified.

Twenty-ninthmulticenterclinicaltrialbyanumberofresearchersinthesametestprograminclinicaltrialsindifferentperiod.Thedesignandimplementationofthetestplanshallatleastincludethefollowingcontents:(a)thetestplanandtheclinicaltrialinstitutionsandresearcherstodiscussidentifiedbytheapplicantorganization,andaclearleadtheunitofclinicaltrialinstitutionforthecoordinationofresearchers;(two)theresearchersresponsibleforcoordinatingtheworkofcoordinationbetweentheinstitutionofclinicaltrialprocessofclinicaltrials,clinicaltrialsinearly,middleandlateorganizationresearchersmeeting,responsiblefortheimplementationandthesponsorofthewholetesttogether;(three)theinstitutionofclinicaltrialtheprincipleshouldbecarriedoutoverthesameperiodandtheendofclinicaltrials;(four)theinstitutionofclinicaltrialtestsamplesizeanddistribution,withstatisticalanalysistoForreason;(5)thesponsorandtheclinicaltestunitsonexperimentaltrainingplanandtrainingrecordsrequirements;(VI)establishedtestdatatransfer,management,queryandverificationprocedure,especiallyclearrequirementsoftheinstitutionofclinicaltrialtestingthedatashouldbetheleadunitcentralizedmanagementandanalysis;(7)aftertheendofthemulticenterclinicaltrials,eachclinicaltrialinstitutionsresearchersshouldrespectivelyissuedasummaryofclinicaltrials,togetherwithacasereporttableinaccordancewiththeprovisionsoftheauditedoverbycoordinatingresearchsummaryreport.Fifthchapterethicscommitteeduties

Article30medicaldeviceclinicaltrialinstitutionethicscommitteeshallbebyatleastfivemembers,includingmedicalprofessionals,medicalprofessionals,whichshouldbethemembersofthedifferentgender.Nonmedicalspecialtycommitteeatleastalegalworkerandanamefortheclinicaltrialinstitutionotherthanthepersonnel.Theethicscommitteeshouldbewiththeassessmentandevaluationoftheclinicaltrialsofscience,medicineandethics,andotheraspectsofqualificationorexperience.Allmembersshouldbefamiliarwithethicalguidelinesfortheclinicaltrialofmedicalapparatusandinstrumentsandrelevantregulationsandabidebytheethicscommitteeoftheconstitution.

Article31medicalethicscommitteeshallcomplywiththeprovisionsofthe<worldmedicalassemblydeclarationofHelsinki>ethicalstandardsandfoodanddrugsupervisionandadministrationdepartmentandestablishthecorrespondingworkingproceduresandtheformationofthefileandworkinaccordancewiththeproceduresperformtheirduties.Theethicscommitteeindependenttomembersoftheresearchersandthesponsorhastherighttocommentandparticipateinrelevanttestvote.

Article32TheEthicsCommitteemeetingshallbenotifiedinadvance,toparticipateinthereviewandthenumberofvotingcannotbelessthanfive,makeanydecisionshouldbebyanethicscommitteecomposedbymorethanhalfofthemembers.Researcherscanprovideinformationonanyaspectoftherelevanttest,butshouldnotparticipateinthereview,voteorcomment.Ethicscommitteeinthereviewofsomespecialtest,caninviteexpertsinrelatedfields.

Thirty-thirdfromtheethicscommitteeshallsafeguardtherightsandinterestsofthesubjectsoftheperspectiveofstrictconsiderationtestschemeandrelateddocuments,andshallfocusonthefollowing:(a)theresearchersqualifications,experienceandwhetherthereissufficienttimetoparticipateintheclinicaltrial.(two)clinicaltrialinstitutionstaffingandequipmentconformtothetest.(three)thesubjectsmaysufferadegreeofriskandbenefitcomparedtotheexpectedtestisappropriate.(four)testprogramisfullyconsideredtheethicalprinciples,withscientificresearchpurposes,includingtheappropriatenessofsubjects'rightsareprotected,otherpersonsmaysuffertheriskandprotectionmethodparticipantsarescience.(five)subjectswereselectedtotestthemethod,therelevantinformationofthesubjectsortheirguardiansprovidedTheinformationiscomplete,whetherthesubjectscouldunderstand,obtaininginformedconsentisappropriate;whennecessary,theethicscommitteeshallorganizetheparticipantsonbehalfofthelevelofunderstandingofthetestdata,theevaluationofinformedconsentisappropriate,theassessmentresultsshallbetheendofthe10yearwrittenrecordandsavetoclinicaltrials(six.)subjectsiftheoccurrenceofclinicaltrialrelatedinjuryordeath,treatmentandinsurancemeasuresforadequacy.(seven)whethertheproposedamendmentstothetestschemeisacceptable.(eight)whethercanbecarriedoutinclinicaltrialsinregularevaluationmayharmtosubjectsfrom(nine).Thetestplanmayaffecttherightsandinterestsofthesubjects,safetyandhealth,oraffectthescientificnature,theintegrityofthetest,whetheritcanbeaccepted.

Ethicalreviewthirty-fourthmulticenterclinicaltrialshouldbeledbytheethicscommitteeresponsiblefortheestablishmentofcollaborativereviewprocedurestoensureconsistencyandtimelinessofthereviewwork.Thebeginningofeachclinicaltrialinstitutionbeforethetestshouldbeledbytheethicscommitteeresponsibleforexaminationandtestschemeofethicalrationalityandscientificity,participateinthetestofotherclinicaltrialinstitutionethicstheCommitteeintheprerequisiteofacceptingtheleadunitethicscommitteereviewcomments,canbeusedtorevieworfilereview,reviewthefeasibilityofthetrialsinthisclinicaltrialinstitutions,includingthequalificationandexperienceoftheequipmentandconditions,generallynolongeronthedesignschemeofthetestproposedamendments,butnotrightapprovedtestinclinicaltrials.

Article35TheEthicsCommitteereceivestheapplicationofclinicaltrialsofmedicaldevicesshallconveneameeting,discussthereview,issueawrittenopinion,seal,andattachedtoattendthemeetingofthepersonnellist,professionalandpersonalsignature.Theviewsoftheethicscommitteemaybe:(a)consent;(II)modificationsnecessaryconsent;(III)withoutconsent;(IV),tosuspendorterminatethetesthasbeenapproved.

Article36TheEthicsCommitteeshallbeofclinicaltrialsofthisclinicaltrialinstitutiontrackingsupervision,itisfoundthatthesubjects'rightsandinterestscannotgetsecuritysituation,canbeinanytimeuponwrittenrequesttosuspendorterminatethetrial.Clinicaltrialshavebeensuspended,withouttheconsentoftheethicscommitteeshouldnotbeallowedtoresume.

Thirty-seventhethicscommitteesshallretainallrecordsrelatingtothecompletionofclinicaltrialsforatleast10years.Thesixthchapteristheresponsibilityoftheapplicant

Article38Thesponsorisresponsibleforinitiating,application,organizationandmonitoringofclinicaltrialsandtheauthenticityofclinicaltrials,responsibleforreliability.Thesponsorisusuallythemedicaldeviceproductionenterprise.Thesponsorforoverseasinstitutionsshallinaccordancewiththeprovisionswithintheterritoryofthepeople'sRepublicofChinaappointedagent.

Article39ThesponsorisresponsiblefororganizingtheformulationandrevisionoftheHandbook,theclinicaltrialsprotocol,informedconsent,casereportform,thestandardoperatingproceduresandotherrelevantdocumentsandisresponsiblefororganizingthetrainingofclinicaltrialsnecessary.

Article40thesponsorshouldaccordingtothecharacteristicsofmedicalapparatusandinstrumentsusedfortesting,intheaccreditationofmedicalinstrumentclinicaltrialinstitutionselectionmechanismtestandresearchwere.Thesponsorbeforetheclinicaltrialagreementsignedinclinicaltrialinstitutionshallclinicaltrialinstitutionsandresearcherstoprovidethelatestresearchmanualandotherrelevantdocuments,foritsdecisionwhethertheycanaffordtheclinicaltrials.

Article41themanualshallincludethefollowingmaincontents:(a)theapplicant,researchersofinformation;(II)testsummaryofmedicaldevicesfor;(III)supporttestmedicaldevicesexpectedoverviewoftheuseandclinicaltrialdesigninreasonandevaluation;and(IV)testwithmedicaldevicemanufacturingwithsuitablemedicalequipmentqualitymanagementsystemrequirementsofthestatement.

Articleforty-secondtheapplicantintheorganizationofthedevelopmentofclinicaltrialsprogrammaynotexaggeratethemechanismandefficacyofmedicaldevices.

Article43inclinicaltrials,thesponsortogetimportantinformationaboutclinicaltrialsshallmodifytheHandbookofresearchandrelateddocumentsintime,andthroughtheclinicaltrialinstitutionofmedicalinstrumentclinicaltrialmanagementdepartmentssubmitethicsreviewcommitteeagreed.

Forty-fourththeapplicantshouldwithclinicaltrialinstitutionsandresearcherstoreachawrittenagreementonthefollowingissues:(a)clinicaltrialimplementationinaccordancewiththerelevantlawsandregulationsandtheclinicaltrialprogram,andaccepttheinspection,verificationandinspection;(two)accordingtothedatarecordingandreportingprocedures;(three)retainthebasicdocumentsandtestthelessthanlessthanthestatutorytime,clinicaltrialsandresearchinstitutionsarenolongerneedtonoticeuntilthesponsorofthedocumentssofar;(four)theapplicantfromtheethicscommitteeapproval,medicalequipmentisresponsibletotheclinicaltrialinstitutionsandresearcherstoprovidetest,anddeterminetheconditionsoftransportandstorageconditions,storagetime,periodofvalidity;(five)testofmedicaldevicesshouldbequalified,itiseasytoidentify,thecorrectencodingandlabeled"test"ofthespeciallogo,andaccordingtotheclinicaltestProgramrequirementsforappropriatepackagingandpreservation;(6)theapplicantshallformulateaclinicaltrialqualitycontrolrelatedSOPs,transportationofmedicaldevicessuchastest,receiving,storage,distribution,processing,recycling,clinicaltrialsresearchorganizationsanddonorfollow.

Article45thesponsortotestwithmedicaldeviceinclinicaltrialsofthesecurityresponsibility.Whenfoundmayinfluencetestimplementationmaychangetheethicscommitteeapprovaltestcontinuesto,thesponsorshallimmediatelynotifyallclinicaltestingmachinestructureandstudytheirsafetyortest,andmakecorrespondingprocessing.

Article46thesponsordecidedtosuspensionorterminationoftheclinicaltrials,itshallnotifyallclinicaltrialinstitutionofmedicaldeviceclinicaltrialmanagementdepartmentin55days,andexplainthereasonsinwrittenform.Clinicaltrialsclinicaltrialsofmedicaldevicesmanagementdepartmentshalltimelynotifythecorrespondingresearchandethicscommittee.Thesuspensionofclinicaltrials,withouttheconsentoftheethicscommitteeandshallnotresume.A

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论